Revelation Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Revelation Biosciences, Inc. carries a market capitalization of 4.06M, placing it among publicly traded companies globally. Its enterprise value stands at -11.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.06M |
| Enterprise Value | -11.72M |
Share Statistics
Revelation Biosciences, Inc. currently has 3.91M shares outstanding.
| Shares Outstanding | 3.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.03 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | -0.19 |
| P/OCF Ratio | -0.19 |
Financial Position
Revelation Biosciences, Inc. maintains a current ratio of 10.02, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.02 |
| Quick Ratio | 9.96 |
| Debt / Equity | 5.84 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -103.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Revelation Biosciences, Inc.'s stock has declined approximately -90.37037% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 3.64.
| Beta (5Y) | N/A |
| 52-Week Price Change | -90.37037% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 3.64 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -10.04M, while operating income came in at -10.07M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -10.07M |
| Pretax Income | -9.87M |
| Net Income | -9.87M |
| EBITDA | -10.04M |
| EBIT | -10.07M |
| Earnings Per Share (EPS) | -7.23 |
Balance Sheet
Revelation Biosciences, Inc. holds 14.11M in cash and equivalents against 759,044.00 in total debt, resulting in a net debt position of -14.11M. Total book value stands at -52.42M, with working capital of 12.79M providing operational flexibility.
| Cash & Cash Equivalents | 14.11M |
| Total Debt | 759,044.00 |
| Net Debt | -14.11M |
| Equity (Book Value) | -52.42M |
| Book Value Per Share | -38.41 |
| Working Capital | 12.79M |
Cash Flow
Revelation Biosciences, Inc. produced -8.69M in operating cash flow over the past twelve months. After subtracting -71,879.00 in capital expenditures, free cash flow totaled -8.76M - equivalent to -6.42 per share.
| Operating Cash Flow | -8.69M |
| Capital Expenditures | -71,879.00 |
| Free Cash Flow | -8.76M |
| FCF Per Share | -6.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,170.42 |
| FCF Yield | -526.16 |
Stock Splits
Revelation Biosciences, Inc.'s most recent stock split took place on January 28, 2026 with a 4:1 split ratio.
| Last Split Date | 1/28/2026 |
| Split Ratio | 4:1 |
Scores
Revelation Biosciences, Inc. posts an Altman Z-Score of -5.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.59 |